Vivos Therapeutics (VVOS) Prices 4M Share Follow-On Offering at $6/Sh

Vivos Therapeutics, Inc. (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the pricing of its underwritten follow-on public offering of 4,000,000 shares of its common stock at a public offering price of $6.00 per share.

The aggregate gross proceeds to Vivos from the public offering are expected to be $24 million prior to deducting underwriting discounts, commissions, and other estimated offering expenses. Vivos has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of common stock to cover over-allotments, if any.

Roth Capital Partners is acting as sole book-running manager and representative of the underwriters for the offering. National Securities Corporation and Craig-Hallum Capital Group are acting as co-managers of the offering.

The Securities and Exchange Commission (“SEC”) declared effective registration statements on Form S-1 relating to these securities on May 6, 2021.

You May Also Be Interested In

• ESS Tech closes $3.2M stock offering at $0.50 per share
• Aveanna Healthcare prices secondary offering at $11.75 per share
• enVVeno Medical (NVNO) files $100M mixed shelf